Icon Plc (NASDAQ:ICLR) had its price target boosted by investment analysts at Jefferies Group LLC from $122.00 to $132.00 in a research note issued on Monday. The firm currently has a “buy” rating on the medical research company’s stock. Jefferies Group LLC’s price target indicates a potential upside of 16.17% from the stock’s current price.

A number of other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine downgraded shares of Icon Plc from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Bank of America Corporation assumed coverage on shares of Icon Plc in a research report on Monday, September 11th. They issued a “buy” rating and a $128.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Icon Plc has an average rating of “Buy” and an average price target of $114.11.

Shares of Icon Plc (NASDAQ:ICLR) traded up 0.31% during trading on Monday, reaching $113.98. 81,340 shares of the company traded hands. Icon Plc has a 12-month low of $73.76 and a 12-month high of $117.53. The firm has a market capitalization of $6.16 billion, a price-to-earnings ratio of 23.12 and a beta of 0.59. The company has a 50 day moving average price of $111.91 and a 200 day moving average price of $96.78.

Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.30 by $0.01. The business had revenue of $431.00 million for the quarter, compared to the consensus estimate of $430.68 million. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $1.14 EPS. On average, equities analysts predict that Icon Plc will post $5.32 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Icon Plc (ICLR) Price Target Increased to $132.00 by Analysts at Jefferies Group LLC” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/09/icon-plc-iclr-price-target-increased-to-132-00-by-analysts-at-jefferies-group-llc.html.

Several large investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC increased its stake in shares of Icon Plc by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after acquiring an additional 24 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Icon Plc by 3.0% in the 2nd quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 67 shares in the last quarter. Huntington National Bank increased its stake in shares of Icon Plc by 5.0% in the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 77 shares in the last quarter. Bangor Savings Bank increased its stake in shares of Icon Plc by 1.4% in the 2nd quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after acquiring an additional 161 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its stake in shares of Icon Plc by 5.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,537 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 168 shares in the last quarter. Institutional investors own 91.53% of the company’s stock.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.